Key Points
- On April 8, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma at an average price of $16.48 (≈$7.98M), leaving it with 4,071,637 shares — a 10.63% reduction in that holding.
- Across early April (Apr 2, 6, 8, 9, 10) Ra Capital sold roughly 1.47 million shares of VOR for about $24.75 million total, indicating notable insider/affiliate liquidation activity.
- Despite the selling, analysts have a consensus Moderate Buy rating with an average price target of $50.67, while VOR trades near $15.47 and institutional investors own about 97.29% of the shares.
Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 828 shares of the business's stock in a transaction on Friday, April 10th. The stock was sold at an average price of $15.75, for a total value of $13,041.00. Following the sale, the director directly owned 3,935,608 shares in the company, valued at $61,985,826. This trade represents a 0.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The stock was sold at an average price of $16.59, for a total value of $2,242,984.59.
- On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The stock was sold at an average price of $16.48, for a total value of $7,978,033.92.
- On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63.
- On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The stock was sold at an average price of $18.23, for a total value of $4,739,800.00.
Vor Biopharma Stock Down 0.8%
Shares of Vor Biopharma stock opened at $15.47 on Friday. The stock's fifty day moving average is $14.41 and its 200-day moving average is $17.16. The firm has a market capitalization of $755.68 million, a PE ratio of -0.04 and a beta of 1.92. Vor Biopharma Inc. has a 12-month low of $2.62 and a 12-month high of $65.80.
Institutional Trading of Vor Biopharma
A number of institutional investors and hedge funds have recently made changes to their positions in VOR. RA Capital Management L.P. lifted its position in shares of Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company's stock worth $70,697,000 after buying an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. lifted its position in shares of Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company's stock worth $47,315,000 after buying an additional 3,237,714 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in shares of Vor Biopharma in the fourth quarter worth about $33,275,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Vor Biopharma in the fourth quarter worth about $22,890,000. Finally, NEXTBio Capital Management LP acquired a new stake in shares of Vor Biopharma in the fourth quarter worth about $13,080,000. Institutional investors and hedge funds own 97.29% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently weighed in on VOR. Wedbush lifted their price target on Vor Biopharma to $15.00 and gave the company a "neutral" rating in a report on Tuesday, March 31st. Citigroup began coverage on Vor Biopharma in a report on Friday, January 9th. They set a "buy" rating and a $50.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Wells Fargo & Company began coverage on Vor Biopharma in a report on Thursday, March 19th. They set an "overweight" rating and a $30.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered their price target on Vor Biopharma from $43.00 to $40.00 and set an "overweight" rating on the stock in a report on Friday, December 19th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $50.67.
Read Our Latest Report on VOR
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.
The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
